Sign in

You're signed outSign in or to get full access.

John Thomas

Director at GENELUX
Board

About John Thomas

John Thomas, Ph.D., 67, is an independent director of Genelux (GNLX) serving since September 2002, and the company’s first Chief Financial Officer from 2002–2004 . He has been Dean of the School of Business and Management at La Sierra University since 1999 and was designated by the Board as an “audit committee financial expert” based on education and prior financial experience . The Board affirmatively determined he is independent under Nasdaq rules . His education includes an M.B.A. in finance (Loma Linda University), an M.B.A. in marketing (Symbiosis Institute of Management Studies), an M.A. in international political economy and a Ph.D. in political economy (Claremont Graduate University) .

Past Roles

OrganizationRoleTenureCommittees/Impact
Genelux CorporationDirectorSep 2002–present Audit Committee Chair; Compensation Committee member; Nominating & Corporate Governance Committee member (FY2024)
Genelux CorporationChief Financial Officer2002–2004 Initial finance leadership during early corporate period
La Sierra UniversityDean, School of Business & Management1999–present Academic leadership; finance expertise credential cited by Board

External Roles

OrganizationRoleTenureNotes
ICON Business BankDirector; Audit Committee ChairSince June 2023 Financial institution governance; audit leadership
KSGN Good News RadioDirectorSince Jan 2004 Non-profit board oversight
Loma Linda Broadcasting Network InternationalDirectorSince Jan 2009 Broadcasting network board
ADRA InternationalFinance Committee memberSince Sept 2015 Humanitarian org finance committee
Family Service AssociationDirector (prior)1992–2018 Public benefit health & human service agency

Board Governance

  • Independence and leadership
    • Independently determined under Nasdaq rules (four of five directors including Thomas) .
    • Audit Committee financial expert designation for Thomas .
    • Board chaired by CEO; Lead Independent Director (Tyree) empowered with strong balancing authorities .
  • Attendance and engagement
    • Board met 8 times in FY2024; each member attended at least 75% of Board and committee meetings; independent directors held 8 executive sessions; all directors attended the 2024 annual meeting .
  • Committee assignments (FY2024)
    • Audit: Chair (Thomas), members Mirabelli, Smither, Tyree; 5 meetings .
    • Compensation: Chair (Smither), members Thomas, Mirabelli; Tyree added Jan 2025; 4 meetings .
    • Nominating & Corporate Governance: Chair (Mirabelli), members Thomas, Smither; 5 meetings .
CommitteeRoleFY2024 Meetings
AuditChair (Thomas) 5
CompensationMember (Thomas) 4
Nominating & Corporate GovernanceMember (Thomas) 5

Fixed Compensation

Metric20232024
Cash/Fees Earned ($)$64,000 $64,000
Total Cash Retainers Structure (policy)Annual cash retainer: $40,000; Audit Chair: $15,000; Compensation Committee member: $5,000; Nominating Committee member: $4,000 Annual cash retainer: $40,000; Audit Chair: $15,000; Compensation Committee member: $5,000; Nominating Committee member: $4,000

Performance Compensation

  • Structure (policy)
    • Annual Grants: Options ($77,500 grant-date value) and RSUs ($77,500 grant-date value); vest on first anniversary or next annual meeting; fully vest upon a change in control; options carry 10-year term with strike equal to grant-date FMV .
  • Director equity awarded to John Thomas
    • 2024 annual RSU grant: 39,541 shares; recorded via Form 4 on Aug 1, 2024 .
    • 2024 annual option grant: 50,469 options; amended strike price $1.96; Form 4/A filed Dec 31, 2024 .
    • 2025 annual RSU grant: 22,283 shares at the Aug 27, 2025 annual meeting .
    • 2025 annual option grant: 28,576 options at $3.64 on Aug 27, 2025 .
Grant YearInstrumentGrant DateQuantityStrike PriceGrant-Date Fair Value (Policy)Vesting
2024RSUs2024-08-0139,541 N/A$77,500 1-year/next annual meeting; CIC full vest
2024Options2024-08-01 (amended)50,469 $1.96 $77,500 1-year/next annual meeting; 10-year term; CIC full vest
2025RSUs2025-08-2722,283 N/APolicy: $77,500 1-year/next annual meeting; CIC full vest
2025Options2025-08-2728,576 $3.64 Policy: $77,500 1-year/next annual meeting; 10-year term; CIC full vest

Other Directorships & Interlocks

Company/OrganizationPublic/PrivateRoleCommittee Role
ICON Business BankPrivate (financial institution)DirectorAudit Committee Chair
KSGN Good News RadioNon-profitDirectorBoard member
Loma Linda Broadcasting Network InternationalNon-profitDirectorBoard member
ADRA InternationalNon-profitFinance Committee memberFinance oversight

Expertise & Qualifications

  • Finance and governance: Audit committee financial expert; prior CFO experience at Genelux; long-tenured dean in business education .
  • Education: M.B.A. (finance), M.B.A. (marketing), M.A., Ph.D. in political economy .

Equity Ownership

Ownership MetricAmountAs-of Date
Total beneficial ownership (shares)618,607 June 30, 2025 (record date)
Beneficial ownership (%)1.6% June 30, 2025
Direct common shares440,960 June 30, 2025
RSUs vesting within 60 days39,541 June 30, 2025
Options exercisable within 60 days135,606 June 30, 2025
Warrants exercisable within 60 days2,500 June 30, 2025
Common shares post 2025 annual grant (Form 4)502,784 Aug 27, 2025
  • Hedging, short sales, margining, and pledging of company stock are prohibited for directors under the Insider Trading and Hedging Policy .

Insider Trades (Form 4/4A/3) – Selected Recent Transactions

DateTypeSecurityQuantityPrice ($)Post-Txn Common OwnedSource
2023-01-30Form 3 (initial)Stock Option (right to buy)25,00010.50N/A
2023-01-30ConversionSeries A Preferred Stock → Common1,410,0000.00N/A
2023-05-02AwardCommon Stock (RSU)9,0000.00479,000
2023-09-11AwardCommon Stock (RSU)3,4600.00482,460
2023-09-11AwardStock Option (Right to Buy)4,39722.404,397 (options)
2023-09-15SaleCommon Stock2,24521.6670480,215
2023-09-18SaleCommon Stock3,33424.9900475,793
2023-10-16SaleCommon Stock2,45220.5014473,341
2023-12-13SaleCommon Stock7,07313.2261465,387
2024-05-29PurchaseCommon Stock2,5004.00465,960
2024-05-29PurchaseCommon Stock Warrant2,5005.252,500 (warrants)
2024-08-01AwardCommon Stock (RSU)39,5410.00505,501
2024-08-01Award (amended)Stock Option (Right to Buy)50,4691.9650,469 (options)
2025-06-06GiftCommon Stock25,0000.00480,501
2025-08-27AwardCommon Stock (RSU)22,2830.00502,784
2025-08-27AwardStock Option (Right to Buy)28,5763.6428,576 (options)

Shareholder Voting Signal (Director Election)

ItemVotes ForVotes WithheldBroker Non-VotesMeeting Date
Election of John Thomas (Class II)9,417,742 5,317,539 7,740,438 Aug 1, 2024

Related Party Transactions & Policies

  • No related party transactions since Jan 1, 2023 exceeding thresholds under Item 404 of Regulation S-K; standard indemnification agreements with directors .
  • Insider Trading & Hedging Policy prohibits hedging, short sales, margins and pledging of company stock by directors .

Director Compensation Mix (YoY)

Component20232024
Cash Fees ($)64,000 64,000
Option Awards ($)77,500 77,500
Stock Awards ($)136,630 77,500
Total ($)278,130 219,000

Governance Assessment

  • Strengths
    • Independence affirmed; long-tenured finance and audit expertise; designated audit committee financial expert .
    • Active committee leadership (Audit Chair) and consistent meeting attendance across Board and committees in FY2024 .
    • Clear anti-hedging/anti-pledging policy; meaningful beneficial ownership (1.6%), including exercisable options and RSUs, supporting alignment .
  • Watch items / RED FLAGS
    • Combined CEO/Chair structure places greater reliance on Lead Independent Director and committee chairs for oversight balance .
    • 2024 director vote showed 5.3M withheld for Thomas versus 1.39M for Mirabelli, indicating comparatively lower support; monitor future vote trends and engagement response .
    • Prior executive (CFO) role may prompt independence scrutiny; Board has reaffirmed independence and absence of disqualifying relationships .
  • Compensation structure
    • Non-employee director pay blends cash retainers with time-based RSUs and options; annual equity fully vests on change-of-control—standard in small-cap biotech, but accelerations can be shareholder-sensitive; no performance-based director metrics disclosed .